Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates

Journal of Experimental Medicine

Volumn 207, Issue 9, 2010, Pages 2003-2017

  Sundling, Christopher ^a   Forsell, Mattias N E ^a   O'Dell, Sijy ^b   Feng, Yu ^b,d   Chakrabarti, Bimal ^b,d   Rao, Srinivas S ^b   Loré, Karin ^a   Mascola, John R ^b   Wyatt, Richard T ^b,d   Douagi, Iyadh ^a   Karlsson Hedestam, Gunilla B ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG 10101; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; POKEWEED MITOGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE ACTIVATION; BINDING AFFINITY; CELL POPULATION; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; STAPHYLOCOCCUS AUREUS; VIRUS ENVELOPE;

ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; MACACA MULATTA; PROTEIN BINDING; SOLUBILITY;

EID: 77956261658     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20100025     Document Type: Article

References (73)

1. Amanna, I.J., and M.K. Slifka. 2006. Quantitation of rare memory B cell populations by two independent and complementary approaches. J. Immunol. Methods. 317:175-185. doi:10.1016/j.jim.2006.09.005
2. Anderson, K.P., C. Lucas, C.V. Hanson, H.F. Londe, A. Izu, T. Gregory, A. Ammann, P.W. Berman, and J.W. Eichberg. 1989. Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1. J. Infect. Dis. 160:960-969.
3. Arpin, C., J. Déchanet, C. Van Kooten, P. Merville, G. Grouard, F. Brière, J. Banchereau, and Y.J. Liu. 1995. Generation of memory B cells and plasma cells in vitro. Science. 268:720-722. doi:10.1126/science.7537388
4. Baba, T.W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehunie, L.A. Cavacini, M.R. Posner, H. Katinger, G. Stiegler, et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206. doi:10.1038/72309
5. Barnett, S.W., I.K. Srivastava, E. Kan, F. Zhou, A. Goodsell, A.D. Cristillo, M.G. Ferrai, D.E. Weiss, N.L. Letvin, D. Montefiori, et al. 2008. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS. 22:339-348. doi:10.1097/QAD. 0b013e3282f3ca57
6. Barnett, S.W., B. Burke, Y. Sun, E. Kan, H. Legg, Y. Lian, K. Bost, F. Zhou, A. Goodsell, J. Zur Megede, et al. 2010. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J. Virol. 84:5975-5985. doi:10.1128/JVI.02533-09
7. Binley, J.M., E.A. Lybarger, E.T. Crooks, M.S. Seaman, E. Gray, K.L. Davis, J.M. Decker, D. Wycuff, L. Harris, N. Hawkins, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668. doi:10.1128/JVI.01762-08
8. Blanchard-Rohner, G., A.S. Pulickal, C.M. Jol-van der Zijde, M.D. Snape, and A.J. Pollard. 2009. Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. Blood. 114:4998-5002. doi:10.1182/blood-2009-03-211052
9. Blink, E.J., A. Light, A. Kallies, S.L. Nutt, P.D. Hodgkin, and D.M. Tarlinton. 2005. Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization. J. Exp. Med. 201:545-554. doi:10.1084/jem.20042060
10. Bogers, W.M., D. Davis, I. Baak, E. Kan, S. Hofman, Y. Sun, D. Mortier, Y. Lian, H. Oostermeijer, Z. Fagrouch, et al. 2008. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology. 382:217-225. doi:10.1016/j.virol.2008.09.016
11. Bonsignori, M., M.A. Moody, R.J. Parks, T.M. Holl, G. Kelsoe, C.B. Hicks, N. Vandergrift, G.D. Tomaras, and B.F. Haynes. 2009. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J. Immunol. 183:2708-2717. doi:10.4049/jimmunol.0901068
12. Burton, D.R., J. Pyati, R. Koduri, S.J. Sharp, G.B. Thornton, P.W. Parren, L.S. Sawyer, R.M. Hendry, N. Dunlop, P.L. Nara, et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 266:1024-1027. doi:10.1126/science.7973652
13. Burton, D.R., R.C. Desrosiers, R.W. Doms, W.C. Koff, P.D. Kwong, J.P. Moore, G.J. Nabel, J. Sodroski, I.A. Wilson, and R.T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236. doi:10.1038/ni0304-233
14. Chakraborty, H., P.K. Sen, R.W. Helms, P.L. Vernazza, S.A. Fiscus, J.J. Eron, B.K. Patterson, R.W. Coombs, J.N. Krieger, and M.S. Cohen. 2001. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS. 15:621-627. doi:10.1097/00002030- 200103300-00012
15. Corti, D., J.P. Langedijk, A. Hinz, M.S. Seaman, F. Vanzetta, B.M. Fernandez-Rodriguez, C. Silacci, D. Pinna, D. Jarrossay, S. Balla- Jhagjhoorsingh, et al. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One. 5:e8805. doi:10.1371/journal.pone.0008805
16. Crotty, S., R.D. Aubert, J. Glidewell, and R. Ahmed. 2004. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods. 286:111-122. doi:10.1016/j.jim.2003.12.015
17. Decker, J.M., F. Bibollet-Ruche, X. Wei, S. Wang, D.N. Levy, W. Wang, E. Delaporte, M. Peeters, C.A. Derdeyn, S. Allen, et al. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201:1407-1419. doi:10.1084/jem.20042510
18. Dhillon, A.K., H. Donners, R. Pantophlet, W.E. Johnson, J.M. Decker, G.M. Shaw, F.H. Lee, D.D. Richman, R.W. Doms, G. Vanham, and D.R. Burton. 2007. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 81:6548-6562. doi:10.1128/JVI.02749-06
19. Doria-Rose, N.A., R.M. Klein, M.M. Manion, S. O'Dell, A. Phogat, B. Chakrabarti, C.W. Hallahan, S.A. Migueles, J. Wrammert, R. Ahmed, et al. 2009. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 83:188-199. doi:10.1128/JVI.01583-08
20. Dosenovic, P., B. Chakrabarti, M. Soldemo, I. Douagi, M.N. Forsell, Y. Li, A. Phogat, S. Paulie, J. Hoxie, R.T. Wyatt, and G.B. Karlsson Hedestam. 2009. Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization. J. Immunol. 183:3373-3382. doi:10.4049/jimmunol.0900407
21. Douagi, I., C. Gujer, C. Sundling, W.C. Adams, A. Smed-Sörensen, R.A. Seder, G.B. Karlsson Hedestam, and K. Loré. 2009. Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J. Immunol. 182:1991-2001. doi:10.4049/jimmunol. 0802257
22. Douagi, I., M.N. Forsell, C. Sundling, S. O'Dell, Y. Feng, P. Dosenovic, Y. Li, R. Seder, K. Loré, J.R. Mascola, et al. 2010. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates. J. Virol. 84:1683-1695. doi:10.1128/JVI.01896-09
23. Forsell, M.N., Y. Li, M. Sundbäck, K. Svehla, P. Liljeström, J.R. Mascola, R. Wyatt, and G.B. Karlsson Hedestam. 2005. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus. J. Virol. 79:10902-10914. doi:10.1128/JVI.79.17.10902-10914.2005
24. Forsell, M.N., B. Dey, A. Mörner, K. Svehla, S. O'dell, C.M. Högerkorp, G. Voss, R. Thorstensson, G.M. Shaw, J.R. Mascola, et al. 2008. B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. PLoS Pathog. 4:e1000171. doi:10.1371/journal.ppat. 1000171
25. Forsell, M.N., W.R. Schief, and R.T. Wyatt. 2009. Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr. Opin. HIV AIDS. 4:380-387. doi:10.1097/COH.0b013e32832edc19
26. Graham, B.S., M.C. Keefer, M.J. McElrath, G.J. Gorse, D.H. Schwartz, K. Weinhold, T.J. Matthews, J.R. Esterlitz, F. Sinangil, and P.E. Fast; NIAID AIDS Vaccine Evaluation Group. 1996. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. Ann. Intern. Med. 125:270-279.
27. Harouse, J.M., A. Gettie, R.C. Tan, J. Blanchard, and C. Cheng-Mayer. 1999. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science. 284:816-819. doi:10.1126/science.284.5415.816
28. Harper, D.M., E.L. Franco, C. Wheeler, D.G. Ferris, D. Jenkins, A. Schuind, T. Zahaf, B. Innis, P. Naud, N.S. De Carvalho, et al; GlaxoSmithKline HPV Vaccine Study Group. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 364:1757-1765. doi:10.1016/S0140-6736(04)17398-4
29. Hessell, A.J., P. Poignard, M. Hunter, L. Hangartner, D.M. Tehrani, W.K. Bleeker, P.W. Parren, P.A. Marx, and D.R. Burton. 2009a. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15:951-954. doi:10.1038/nm.1974
30. Hessell, A.J., E.G. Rakasz, P. Poignard, L. Hangartner, G. Landucci, D.N. Forthal, W.C. Koff, D.I. Watkins, and D.R. Burton. 2009b. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433. doi:10.1371/journal.ppat.1000433
31. Huber, M., and A. Trkola. 2007. Humoral immunity to HIV-1: neutralization and beyond. J. Intern. Med. 262:5-25. doi:10.1111/j.1365-2796.2007.01819.x
32. Huggins, J., T. Pellegrin, R.E. Felgar, C. Wei, M. Brown, B. Zheng, E.C. Milner, S.H. Bernstein, I. Sanz, and M.S. Zand. 2007. CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells. Blood. 109:1611-1619. doi:10.1182/blood-2006-03-008441
33. Joura, E.A., S. Leodolter, M. Hernandez-Avila, C.M. Wheeler, G. Perez, L.A. Koutsky, S.M. Garland, D.M. Harper, G.W. Tang, D.G. Ferris, et al. 2007. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 369:1693-1702. doi:10.1016/S0140-6736(07)60777-6
34. Karlsson Hedestam, G.B., R.A. Fouchier, S. Phogat, D.R. Burton, J. Sodroski, and R.T. Wyatt. 2008. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 6:143-155. doi:10.1038/nrmicro1819
35. Kozlowski, P.A., and M.R. Neutra. 2003. The role of mucosal immunity in prevention of HIV transmission. Curr. Mol. Med. 3:217-228. doi:10.2174/ 1566524033479852
36. Kraft, Z., N.R. Derby, R.A. McCaffrey, R. Niec, W.M. Blay, N.L. Haigwood, E. Moysi, C.J. Saunders, T. Wrin, C.J. Petropoulos, et al. 2007. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J. Virol. 81:6402-6411. doi:10.1128/JVI.00424-07
37. Krieg, A.M., A.K. Yi, S. Matson, T.J. Waldschmidt, G.A. Bishop, R. Teasdale, G.A. Koretzky, and D.M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:546-549. doi:10.1038/374546a0
38. Lai, L., D. Vödrös, P.A. Kozlowski, D.C. Montefiori, R.L. Wilson, V.L. Akerstrom, L. Chennareddi, T. Yu, S. Kannanganat, L. Ofielu, et al. 2007. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology. 369:153-167. doi:10.1016/j.virol.2007. 07.017
39. Leutenegger, C.M., J. Higgins, T.B. Matthews, A.F. Tarantal, P.A. Luciw, N.C. Pedersen, and T.W. North. 2001. Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA. AIDS Res. Hum. Retroviruses. 17:243-251. doi:10.1089/088922201750063160
40. Li, M., F. Gao, J.R. Mascola, L. Stamatatos, V.R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K.M. Greene, et al. 2005. Human immunode- ficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125. doi:10.1128/JVI.79.16.10108-10125.2005
41. Li, Y., K. Svehla, N.L. Mathy, G. Voss, J.R. Mascola, and R. Wyatt. 2006. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J. Virol. 80:1414-1426. doi:10.1128/JVI.80.3.1414-1426.2006
42. Li, Y., S.A. Migueles, B. Welcher, K. Svehla, A. Phogat, M.K. Louder, X. Wu, G.M. Shaw, M. Connors, R.T. Wyatt, and J.R. Mascola. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13:1032-1034. doi:10.1038/nm1624
43. Liu, F., P.L. Bergami, M. Duval, D. Kuhrt, M. Posner, and L. Cavacini. 2003. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120. AIDS Res. Hum. Retroviruses. 19:597-607. doi:10.1089/088922203322230969
44. Lubeck, M.D., R. Natuk, M. Myagkikh, N. Kalyan, K. Aldrich, F. Sinangil, S. Alipanah, S.C. Murthy, P.K. Chanda, S.M. Nigida Jr., et al. 1997. Longterm protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 3:651-658. doi:10.1038/nm0697-651
45. Mamani-Matsuda, M., A. Cosma, S. Weller, A. Faili, C. Staib, L. Garçon, O. Hermine, O. Beyne-Rauzy, C. Fieschi, J.O. Pers, et al. 2008. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood. 111:4653-4659. doi:10.1182/blood-2007-11-123844
46. Marrack, P., A.S. McKee, and M.W. Munks. 2009. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9:287-293. doi:10.1038/nri2510
47. Mascola, J.R., G. Stiegler, T.C. VanCott, H. Katinger, C.B. Carpenter, C.E. Hanson, H. Beary, D. Hayes, S.S. Frankel, D.L. Birx, and M.G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210. doi:10.1038/72318
48. McAleer, W.J., E.B. Buynak, R.Z. Maigetter, D.E. Wampler, W.J. Miller, and M.R. Hilleman. 1984. Human hepatitis B vaccine from recombinant yeast. Nature. 307:178-180. doi:10.1038/307178a0
49. Montefiori, D.C., B.S. Graham, S. Kliks, and P.F. Wright; NIAID AIDS Vaccine Clinical Trials Network. 1992. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. J. Clin. Immunol. 12:429-439. doi:10.1007/BF00918855
50. Moore, P.L., E.S. Gray, I.A. Choge, N. Ranchobe, K. Mlisana, S.S. Abdool Karim, C. Williamson, and L. Morris; CAPRISA 002 Study Team. 2008. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J. Virol. 82:1860-1869. doi:10.1128/JVI.02187-07
51. Mörner, A., I. Douagi, M.N. Forsell, C. Sundling, P. Dosenovic, S. O'Dell, B. Dey, P.D. Kwong, G. Voss, R. Thorstensson, et al. 2009. Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J. Virol. 83:540-551. doi:10.1128/JVI.01102-08
52. Nimmerjahn, F., and J.V. Ravetch. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8:34-47. doi:10.1038/nri2206
53. Pantophlet, R., and D.R. Burton. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24:739-769. doi:10.1146/annurev.immunol. 24.021605.090557
54. Parren, P.W., P.A. Marx, A.J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J.P. Moore, and D.R. Burton. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-8347. doi:10.1128/JVI.75.17.8340-8347.2001
55. Pilcher, C.D., H.C. Tien, J.J. Eron Jr., P.L. Vernazza, S.Y. Leu, P.W. Stewart, L.E. Goh, and M.S. Cohen; Quest Study; Duke-UNC-Emory Acute HIV Consortium. 2004. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189:1785-1792. doi:10.1086/386333
56. Pitisuttithum, P., P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J.W. Tappero, and K. Choopanya; Bangkok Vaccine Evaluation Group. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-1671. doi:10.1086/508748
57. Polacino, P., K. Larsen, L. Galmin, J. Suschak, Z. Kraft, L. Stamatatos, D. Anderson, S.W. Barnett, R. Pal, K. Bost, et al. 2008. Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques. J. Med. Primatol. 37:13-23. doi:10.1111/j.1600-0684.2008.00325.x
58. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, et al; MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220. doi:10.1056/NEJMoa0908492
59. Rojas, R., and G. Apodaca. 2002. Immunoglobulin transport across polarized epithelial cells. Nat. Rev. Mol. Cell Biol. 3:944-955. doi:10.1038/nrm972
60. Sather, D.N., J. Armann, L.K. Ching, A. Mavrantoni, G. Sellhorn, Z. Caldwell, X. Yu, B. Wood, S. Self, S. Kalams, and L. Stamatatos. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769. doi:10.1128/JVI.02036-08
61. Scheid, J.F., H. Mouquet, N. Feldhahn, B.D. Walker, F. Pereyra, E. Cutrell, M.S. Seaman, J.R. Mascola, R.T. Wyatt, H. Wardemann, and M.C. Nussenzweig. 2009a. A method for identification of HIV gp140 binding memory B cells in human blood. J. Immunol. Methods. 343:65-67. doi:10.1016/j.jim.2008.11. 012
62. Scheid, J.F., H. Mouquet, N. Feldhahn, M.S. Seaman, K. Velinzon, J. Pietzsch, R.G. Ott, R.M. Anthony, H. Zebroski, A. Hurley, et al. 2009b. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 458:636-640. doi:10.1038/nature07930
63. Schwickert, T.A., B. Alabyev, T. Manser, and M.C. Nussenzweig. 2009. Germinal center reutilization by newly activated B cells. J. Exp. Med. 206:2907-2914. doi:10.1084/jem.20091225
64. Shu, Y., S. Winfrey, Z.Y. Yang, L. Xu, S.S. Rao, I. Srivastava, S.W. Barnett, G.J. Nabel, and J.R. Mascola. 2007. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine. 25:1398-1408. doi:10.1016/j.vaccine.2006.10.046
65. Simek, M.D., W. Rida, F.H. Priddy, P. Pung, E. Carrow, D.S. Laufer, J.K. Lehrman, M. Boaz, T. Tarragona-Fiol, G. Miiro, et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-7348. doi:10.1128/JVI.00110-09
66. Stamatatos, L., L. Morris, D.R. Burton, and J.R. Mascola. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15:866-870.
67. Sundling, C., K. Schön, A. Mörner, M.N. Forsell, R.T. Wyatt, R. Thorstensson, G.B. Karlsson Hedestam, and N.Y. Lycke. 2008. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J. Gen. Virol. 89:2954-2964. doi:10.1099/vir.0.2008/005470-0
68. Vermont, C.L., H.H. van Dijken, C.J. van Limpt, R. de Groot, L. van Alphen, and G.P. van Den Dobbelsteen. 2002. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infect. Immun. 70:584-590. doi:10.1128/IAI.70.2. 584-590.2002
69. Walker, L.M., S.K. Phogat, P.Y. Chan-Hui, D. Wagner, P. Phung, J.L. Goss, T. Wrin, M.D. Simek, S. Fling, J.L. Mitcham, et al; Protocol G Principal Investigators. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 326:285-289. doi:10.1126/science.1178746
70. Wrammert, J., K. Smith, J. Miller, W.A. Langley, K. Kokko, C. Larsen, N.Y. Zheng, I. Mays, L. Garman, C. Helms, et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 453:667-671. doi:10.1038/nature06890
71. Wu, X., Z.Y. Yang, Y. Li, C.-M. Hogerkorp, W.R. Schief, M.S. Seaman, T. Zhou, K. McKee, S. O'Dell, M.K. Louder, et al. 2010. Rational design of envelope surface identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 10.1126/science.1187659.
72. Yang, X., M. Farzan, R. Wyatt, and J. Sodroski. 2000. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 74:5716-5725. doi:10.1128/JVI.74.12.5716-5725.2000
73. Yang, X., J. Lee, E.M. Mahony, P.D. Kwong, R. Wyatt, and J. Sodroski. 2002. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76:4634-4642. doi:10.1128/JVI.76.9.4634-4642.2002